The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer

Journal of Clinical Investigation

Volumn 117, Issue 1, 2007, Pages 218-228

  Bosco, Emily E ^a   Wang, Ying ^a   Xu, Huan ^b   Zilfou, Jack T ^c   Knudsen, Karen E ^a   Aronow, Bruce J ^b   Lowe, Scott W ^c,d   Knudsen, Erik S ^a,e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CISPLATIN; CYCLIN E; FULVESTRANT; RETINOBLASTOMA PROTEIN; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE TARGETING; GENOME; HUMAN; HUMAN CELL; IONIZING RADIATION; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; XENOGRAFT;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; G1 PHASE; GENE DELETION; HUMANS; IMMUNOBLOTTING; RETINOBLASTOMA PROTEIN; S PHASE;

EID: 33845972969     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28803     Document Type: Article

References (57)

1. Jensen, E.V., and Jordan, V.C. 2003. The estrogen receptor: a model for molecular medicine. Clin. Cancer Res. 9:1980-1989.
2. Sutherland, R.L., Green, M.D., Hall, R.E., Reddel, R.R., and Taylor, I.W. 1983. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur. J. Cancer Clin. Oncol. 19:615-621.
3. Osborne, C.K., Boldt, D.H., Clark, G.M., and Trent, J.M. 1983. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res. 43:3583-3585.
4. Encarnacion, C.A., et al. 1993. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26:237-246.
5. Howell, A., and Robertson, J. 1995. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 345:989-990.
6. Robertson, J.F. 1996. Oestrogen receptor: a stable phenotype in breast cancer. Br. J. Cancer. 73:5-12.
7. Broceno, C., Wilkie, S., and Mittnacht, S. 2002. RB activation defect in tumor cell lines. Proc. Natl. Acad. Sci. U. S. A. 99:14200-14205.
8. Foster, J.S., Henley, D.C., Bukovsky, A., Seth, P., and Wimalasena, J. 2001. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function. Mol. Cell. Biol. 21:794-810.
9. Sutherland, R.L., and Musgrove, E.A. 2004. Cyclins and breast cancer. J. Mammary Gland Biol. Neoplasia. 9:95-104.
10. Carroll, J.S., Prall, O.W., Musgrove, E.A., and Sutherland, R.L. 2000. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. J. Biol. Chem. 275:38221-38229.
11. Watts, C.K., et al. 1995. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol. Endocrinol. 9:1804-1813.
12. Pietilainen, T., et al. 1995. Expression of retinoblastoma gene protein (Rb) in breast cancer as related to established prognostic factors and survival. Eur. J. Cancer. 31A:329-333.
13. Oesterreich, S., and Fuqua, S.A. 1999. Tumor suppressor genes in breast cancer. Endocr. Relat. Cancer. 6:405-419.
14. Chano, T., Kontani, K., Teramoto, K., Okabe, H., and Ikegawa, S. 2002. Truncating mutations of RB1CC1 in human breast cancer. Nat. Genet. 31:285-288.
15. Borg, A., Zhang, Q.X., Alm, P., Olsson, H., and Sellberg, G. 1992. The retinoblastoma gene in breast cancer: allele loss is not correlated with loss of gene protein expression. Cancer Res. 52:2991-2994.
16. Ceccarelli, C., et al. 1998. Retinoblastoma (RB1) gene product expression in breast carcinoma. Correlation with Ki-67 growth fraction and biopathological profile. J. Clin. Pathol. 51:818-824.
17. Malumbres, M., and Barbacid, M. 2001. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer. 1:222-231.
18. Dai, H., et al. 2005. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res. 65:4059-4066.
19. Zhou, R., Frum, R., Deb, S., and Deb, S.P. 2005. The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells. Cancer Res. 65:1839-1848.
20. Sheard, M.A., Uldrijan, S., and Vojtesek, B. 2003. Role of p53 in regulating constitutive and X-radiation-inducible CD95 expression and function in carcinoma cells. Cancer Res. 63:7176-7184.
21. Sheen, J.H., and Dickson, R.B. 2002. Overexpression of c-Myc alters G(1)/S arrest following ionizing radiation. Mol. Cell. Biol. 22:1819-1833.
22. Ma, X.J., et al. 2004. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 5:607-616.
23. Bhattacharjee, A., et al. 2001. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98:13790-13795.
24. Nielsen, N.H., Emdin, S.O., Cajander, J., and Landberg, G. 1997. Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein. Oncogene. 14:295-304.
25. Sherr, C.J., and McCormick, F. 2002. The RB and p53 pathways in cancer. Cancer Cell. 2:103-112.
26. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
27. Dimova, D.K., and Dyson, N.J. 2005. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 24:2810-2826.
28. Sage, J., et al. 2000. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev. 14:3037-3050.
29. Mayhew, C.N., et al. 2004. Discrete signaling pathways participate in RB-dependent responses to chemotherapeutic agents. Oncogene. 23:4107-4120.
30. Harrington, E.A., Bruce, J.L., Harlow, E., and Dyson, N. 1998. pRB plays an essential role in cell cycle arrest induced by DNA damage. Proc. Natl. Acad. Sci. U. S. A. 95:11945-11950.
31. Almasan, A., Linke, S.P., Paulson, T.G., Huang, L.C., and Wahl, G.M. 1995. Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev. 14:59-73.
32. Harbour, J.W., and Dean, D.C. 2000. Rb function in cell-cycle regulation and apoptosis. Nat. Cell Biol. 2:E65-E67.
33. Nahle, Z., et al. 2002. Direct coupling of the cell cycle and cell death machinery by E2F. Nat. Cell Biol. 4:859-864.
34. Bracken, A.P., Ciro, M., Cocito, A., and Helin, K. 2004. E2F target genes: unraveling the biology. Trends Biochem. Sci. 29:409-417.
35. Borresen-Dale, A.L. 2003. TP53 and breast cancer. Hum. Mutat. 21:292-300.
36. Essmann, F., Engels, I.H., Totzke, G., Schulze-Osthoff, K., and Janicke, R.U. 2004. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res. 64:7065-7072.
37. Leung, B.S., and Potter, A.H. 1987. Mode of estrogen action on cell proliferative kinetics in CAMA-1 cells. I. Effect of serum and estrogen. Cancer Invest. 5:187-194.
38. Jordan, V.C., and Morrow, M. 2003. Re: trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J. Natl. Cancer Inst. 95:683-684; author reply 684-685.
39. Osborne, C.K., Schiff, R., Fuqua, S.A., and Shou, J. 2001. Estrogen receptor: current understanding of its activation and modulation. Clin. Cancer Res. 7:4338s-4342s; discussion 4411s-4412s.
40. Nicholson, R.I., and Johnston, S.R. 2005. Endocrine therapy - current benefits and limitations. Breast Cancer Res. Treat. 93(Suppl. 1):S3-S10.
41. Shou, J., et al. 2004. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J. Natl. Cancer Inst. 96:926-935.
42. Jordan, V.C., and Murphy, C.S. 1990. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 11:578-610.
43. Michalides, R., et al. 2002. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer. 86:402-408.
44. Dhillon, N.K., and Mudryj, M. 2002. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene. 21:4626-4634.
45. Naderi, A., et al. 2006. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. doi:10.1038/sj.onc.1209920.
46. Sorlie, T., et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98:10869-10874.
47. Sotiriou, C., et al. 2006. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer Inst. 98:262-272.
48. van de Vijver, M.J., et al. 2002. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347:1999-2009.
49. Lee, E.Y., et al. 1988. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science. 241:218-221.
50. Loden, M., et al. 2002. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene. 21:4680-4690.
51. Pacilio, C., et al. 1998. Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res. 58:871-876.
52. Bindels, E.M., Lallemand, F., Balkenende, A., Verwoerd, D., and Michalides, R. 2002. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells. Oncogene. 21:8158-8165.
53. Wang, S., Zhang, B., and Faller, D.V. 2004. BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists. EMBO J. 23:2293-2303.
54. Cariou, S., et al. 2000. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 97:9042-9046.
55. Wise-Draper, T.M., et al. 2006. Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions. Mol. Cell. Biol. 26:7506-7519.
56. Bosco, E.E., et al. 2004. RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult. Nucleic Acids Res. 32:25-34.
57. Markey, M.P., et al. 2002. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res. 62:6587-6597.